Pfizer Inc. $PFE Shares Bought by Arnhold LLC

Arnhold LLC grew its position in shares of Pfizer Inc. (NYSE:PFE) by 23.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 959,797 shares of the biopharmaceutical company’s stock after acquiring an additional 183,299 shares during the quarter. Pfizer comprises 1.8% of Arnhold LLC’s portfolio, making the stock its 13th biggest position. Arnhold LLC’s holdings in Pfizer were worth $23,899,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the stock. Wellington Shields & Co. LLC grew its stake in shares of Pfizer by 2.5% in the fourth quarter. Wellington Shields & Co. LLC now owns 80,956 shares of the biopharmaceutical company’s stock valued at $2,016,000 after buying an additional 1,965 shares in the last quarter. Sterling Investment Advisors Ltd. grew its stake in shares of Pfizer by 5.4% in the fourth quarter. Sterling Investment Advisors Ltd. now owns 97,560 shares of the biopharmaceutical company’s stock valued at $2,429,000 after buying an additional 5,000 shares in the last quarter. Allied Investment Advisors LLC grew its stake in shares of Pfizer by 3.7% in the fourth quarter. Allied Investment Advisors LLC now owns 371,263 shares of the biopharmaceutical company’s stock valued at $9,244,000 after buying an additional 13,216 shares in the last quarter. Harbour Investments Inc. grew its stake in shares of Pfizer by 25.9% in the fourth quarter. Harbour Investments Inc. now owns 97,829 shares of the biopharmaceutical company’s stock valued at $2,436,000 after buying an additional 20,136 shares in the last quarter. Finally, Allstate Corp grew its stake in shares of Pfizer by 105.0% in the fourth quarter. Allstate Corp now owns 418,638 shares of the biopharmaceutical company’s stock valued at $10,424,000 after buying an additional 214,443 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.1%

Shares of PFE opened at $25.92 on Tuesday. The company has a market capitalization of $147.72 billion, a P/E ratio of 19.79 and a beta of 0.35. Pfizer Inc. has a one year low of $22.88 and a one year high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a 50-day moving average price of $26.84 and a 200 day moving average price of $26.25.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PFE shares. Citigroup increased their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. CICC Research started coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price for the company. Barclays started coverage on Pfizer in a research note on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price for the company. Finally, Guggenheim increased their target price on Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $28.61.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.